Sat, Apr 21, 2018 - Page 10 News List

Takeda shares slide after failed takeover


Shares in Japanese drug maker Takeda Pharmaceutical Co yesterday dropped 4.67 percent after it confirmed an unsuccessful US$60 billion takeover bid for Irish drugmaker Shire PLC.

The proposal was rejected, but “discussions between the parties regarding a potential offer are ongoing,” Takeda said.

Meanwhile, a potential rival in its bid to take over Shire said it was no longer considering making an offer.

Analysts had raised the prospect of a bidding war between Takeda and Botox maker Allergan PLC after the global pharma giant said it was also considering making a bid for Shire.

However, Allergan late on Thursday said in a statement that it now “does not intend to make an offer for Shire.”

Takeda’s shares closed at ¥4,857 in Tokyo. Shire yesterday fell as much as 4.4 percent early in London as the prospect of a bidding war receded. Its US depositary receipts closed down 1.1 percent to US$160.74 a share in New York.

Takeda’s cash-and-shares offer valued Shire at £42 billion (US$59 billion) and was pitched at the equivalent of £46.50 per share.

Shire, which is based in Dublin, but listed in London, said in a statement that it had rejected three takeover approaches from Takeda because they all “significantly undervalued the company, its growth prospects and pipeline.”

However, Shire added that its advisers have entered a dialogue with Takeda to discuss “whether a further, more attractive, proposal may be forthcoming.”

Takeda has been ramping up its takeover ambitions under chief executive officer Christophe Weber as the company seeks growth overseas amid patent expirations and a shrinking domestic population.

A Shire takeover would be Takeda’s largest-ever deal by far. Its most expensive previous purchase was a US$13.7 billion takeover of Nycomed A/S in 2011.

Last year, the company expanded its footprint in the US oncology market with the US$4.7 billion purchase of Ariad Pharmaceuticals Inc.

However, some analysts are concerned that a takeover bid of this magnitude could put too much pressure on Takeda’s own finances.

Additional reporting by Bloomberg

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top